Travere Therapeutics
TVTX
154 hedge funds and large institutions have $1.53B invested in Travere Therapeutics in 2022 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 72 increasing their positions, 53 reducing their positions, and 28 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 53
20% more call options, than puts
Call options by funds: $1.36M | Put options by funds: $1.13M
4.47% more ownership
Funds ownership: 109.05% → 113.53% (+4.5%)
10% less funds holding
Funds holding: 171 → 154 (-17)
11% less capital invested
Capital invested by funds: $1.72B → $1.53B (-$186M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
50% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$25M |
| 2 |
State Street
Boston,
Massachusetts
|
+$17.2M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$12.3M |
| 4 |
AC
Armistice Capital
New York
|
+$12.2M |
| 5 |
BlackRock
New York
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$44M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$19.9M |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$11M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$10.4M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.07M |
TVTX Hedge Fund Activity: Q4 2022 in Review
154 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q4 2022, worth a combined $1.53B — down 11% from $1.72B a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of TVTX and 14 opened new positions — a net loss of 14 holders — while 53 trimmed existing stakes and 72 added.
The largest buyer was Janus Henderson Group, adding an estimated $25M. The largest seller was Baker Bros. Advisors, cutting an estimated $44M.
- 154 institutional investors held Travere Therapeutics (TVTX) as of Q4 2022, down from 171 in Q3 2022.
- Funds reported $1.53B of Travere Therapeutics stock for Q4 2022, down 11% quarter-over-quarter.
- 14 funds opened new Travere Therapeutics positions in Q4 2022 and 28 closed out, a net change of -14 holders.
- The largest Travere Therapeutics buyer in Q4 2022 was Janus Henderson Group, an estimated $25M added.
- The largest Travere Therapeutics seller in Q4 2022 was Baker Bros. Advisors, an estimated $44M sold.
Based on aggregated 13F filings for Q4 2022.